Provides batch-specific identity and purity documentation for research review
One vial, four weeks, done
The OPTIONS study was described as a double-blind, placebo-controlled trial in 502 adults with obesity who received oral AOD9604 or placebo once daily for 24 weeks together with a diet-and-exercise program
Marketing authorization holder ZENTIVA FRANCE 35 RUE DU VAL DE MARNE 75013 PARIS Marketing authorization holder ZENTIVA FRANCE 35 RUE DU VAL DE MARNE 75013 PARIS Manufacturer DELPHARM DIJON 6 BOULEVARD DE LEUROPE 21800 QUETIGNY Or FAMAR HEALTH CARE SERVICES MADRID S.A.U AVDA DE LEGANES N 62 ALCORCON 28925 MADRID Spain Product names in member states of the European Economic Area Not applicable
It stimulates fat breakdown and oxidation while helping prevent new fat storage, particularly in areas where stubborn fat tends to accumulate
(3) F M Ng, J Sun, L Sharma, R Libinaka, et al (2000)